A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, S.H. | - |
dc.contributor.author | Lim, D.H. | - |
dc.contributor.author | Sohn, T.S. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Zang, D.Y. | - |
dc.contributor.author | Kim, S.T. | - |
dc.contributor.author | Kang, J.H. | - |
dc.contributor.author | Oh, S.Y. | - |
dc.contributor.author | Hwang, I.G. | - |
dc.contributor.author | Ji, J.H. | - |
dc.contributor.author | Shin, D.B. | - |
dc.contributor.author | Yu, J.I. | - |
dc.contributor.author | Kim, K.-M. | - |
dc.contributor.author | An, J.Y. | - |
dc.contributor.author | Choi, M.G. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Hong, J.Y. | - |
dc.contributor.author | Park, J.O. | - |
dc.contributor.author | Park, Y.S. | - |
dc.contributor.author | Lim, H.Y. | - |
dc.contributor.author | Bae, J.M. | - |
dc.contributor.author | Kang, W.K. | - |
dc.contributor.author | ARTIST 2 investigators | - |
dc.date.accessioned | 2021-07-26T04:52:16Z | - |
dc.date.available | 2021-07-26T04:52:16Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.issn | 1569-8041 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/47819 | - |
dc.description.abstract | Background: Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II or III, node-positive GC. Patients and methods: The ARTIST 2 compared, in a 1:1:1 ratio, three adjuvant regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 weeks off) for 1 year, S-1 (2 weeks on/1 week off) plus oxaliplatin 130 mg/m2 every 3 weeks (SOX) for 6 months, and SOX plus chemoradiotherapy 45 Gy (SOXRT). Randomization was stratified according to surgery type (total or subtotal gastrectomy), pathologic stage (II or III), and Lauren histologic classification (diffuse or intestinal/mixed). The primary endpoint was disease-free survival (DFS) at 3 years; a reduction of 33% in the hazard ratio (HR) for DFS with SOX or SOXRT, when compared with S-1, was considered clinically meaningful. The trial is registered at clinicaltrials.gov (NCT0176146). Results: A total of 546 patients were recruited between February 2013 and January 2018 with 182, 181, and 183 patients in the S-1, SOX, and SOXRT arms, respectively. Median follow-up period was 47 months, with 178 DFS events observed. Estimated 3-year DFS rates were 64.8%, 74.3%, and 72.8% in the S-1, SOX, and SOXRT arms, respectively. HR for DFS in the control arm (S-1) was shorter than that in the SOX and SOXRT arms: S-1 versus SOX, 0.692 (P = 0.042) and S-1 versus SOXRT, 0.724 (P = 0.074). No difference in DFS was found between SOX and SOXRT (HR 0.971; P = 0.879). Adverse events were as anticipated in each arm, and were generally well-tolerated and manageable. Conclusions: In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 monotherapy. The addition of radiotherapy to SOX did not significantly reduce the rate of recurrence after D2 gastrectomy. © 2020 The Authors | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Ltd | - |
dc.title | A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆ | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.annonc.2020.11.017 | - |
dc.identifier.bibliographicCitation | Annals of Oncology, v.32, no.3, pp 368 - 374 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000629497100012 | - |
dc.identifier.scopusid | 2-s2.0-85100080758 | - |
dc.citation.endPage | 374 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 368 | - |
dc.citation.title | Annals of Oncology | - |
dc.citation.volume | 32 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | adjuvant chemotherapy | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | radiotherapy | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.